China's drug regulator approved Sichuan Biokin Pharmaceutical's (SHA:688506) clinical trial for its BL-M08D1 injection as a combination therapy for diffuse large B-cell lymphoma, according to a Friday filing with the Shanghai bourse.
Diffuse large B-cell lymphoma is the most common subtype of non-Hodgkin lymphoma, according to the Mayo Clinic.
BL-M08D1 is also undergoing phase 1B trials for relapsed or refractory hematologic malignancies and locally advanced tumors.
(Corrects the first paragraph to fix a typo and clarify the unit's name)GuocoLand's (SGX:F17) Malaysia-listed unit, GuocoLand (Malaysia) (KLSE:GUOCO), filed a formal petition with the High Court of Malaysia to confirm its proposed share capital reduction and repayment framework, according to a Thursday filing.The court application, submitted on June 4, serves as the primary legal step remaining to execute the company's privatization via a selective capital reduction mechanism.This follows the property developer's shareholders approving the proposed privatization of the company at an extraordinary general meeting held on May 29.
Mabwell (Shanghai) Bioscience (HKG:2493, SHA:688062) has received regulatory approval in China and the U.S. to begin clinical trials of 9MW5211, which targets inflammatory bowel disease (IBD), according to a Thursday filing with the Hong Kong bourse.The company's Hong Kong shares fell over 1% in morning trade Friday.
Sichuan Biokin Pharmaceutical (SHA:688506) completed the enrollment of its first subject in the Phase III clinical trial on BL-M05D1 injection, according to a Shanghai bourse filing on Friday.The drug is being tested as a treatment for patients with Claudin18.2-positive advanced gastric cancer or gastroesophageal junction adenocarcinoma who have previously received first-line therapy.